Table 1.
Baseline Characteristics of the Study Population
| Characteristic | All (N=99) | ViTAVR (N=25) | ViSAVR (N=74) | P Value (Overall) |
|---|---|---|---|---|
| Age, y | 80.0 (73.0–86.0) | 83.0 (80.0–86.0) | 77.0 (69.2–86.0) | 0.058 |
| Women | 0.526 | |||
| No | 47 (47.5) | 10 (40.0) | 37 (50.0) | |
| Yes | 52 (52.5) | 15 (60.0) | 37 (50.0) | |
| STS score | 7.15 (4.31–13.4) | 7.44 (5.65–14.2) | 6.80 (3.74–12.3) | 0.066 |
| NYHA functional class | 0.328 | |||
| II | 3 (3.06) | 1 (4.00) | 2 (2.74) | |
| III | 48 (49.0) | 15 (60.0) | 33 (45.2) | |
| IV | 47 (48.0) | 9 (36.0) | 38 (52.1) | |
| CCS class | 0.118 | |||
| 0 | 78 (80.4) | 18 (72.0) | 60 (83.3) | |
| I | 7 (7.22) | 1 (4.00) | 6 (8.33) | |
| II | 8 (8.25) | 3 (12.0) | 5 (6.94) | |
| III | 3 (3.09) | 2 (8.00) | 1 (1.39) | |
| IV | 1 (1.03) | 1 (4.00) | 0 (0.00) | |
| Diabetes mellitus | 0.115 | |||
| No | 69 (70.4) | 14 (56.0) | 55 (75.3) | |
| Yes | 29 (29.6) | 11 (44.0) | 18 (24.7) | |
| Chronic obstructive lung disease | 0.006 | |||
| No | 64 (64.6) | 10 (40.0) | 54 (73.0) | |
| Yes | 35 (35.4) | 15 (60.0) | 20 (27.0) | |
| Creatinine clearance <60, ml/min | 0.920 | |||
| No | 42 (42.9) | 10 (40.0) | 32 (43.8) | |
| Yes | 56 (57.1) | 15 (60.0) | 41 (56.2) | |
| Previous coronary artery bypass surgery | 0.319 | |||
| No | 61 (61.6) | 18 (72.0) | 43 (58.1) | |
| Yes | 38 (38.4) | 7 (28.0) | 31 (41.9) | |
| Previous PCI | 0.304 | |||
| No | 86 (86.9) | 20 (80.0) | 66 (89.2) | |
| Yes | 13 (13.1) | 5 (20.0) | 8 (10.8) | |
| Previous TIA or stroke | 1.000 | |||
| No | 77 (77.8) | 19 (76.0) | 58 (78.4) | |
| Yes | 22 (22.2) | 6 (24.0) | 16 (21.6) | |
| Permanent aFib | 0.580 | |||
| No | 62 (62.6) | 14 (56.0) | 48 (64.9) | |
| Yes | 37 (37.4) | 11 (44.0) | 26 (35.1) | |
| Permanent pacemaker or defibrillator | 1.000 | |||
| No | 77 (79.4) | 20 (80.0) | 57 (79.2) | |
| Yes | 20 (20.6) | 5 (20.0) | 15 (20.8) | |
| Ejection fraction, % | 60.0 (45.0–65.5) | 59.0 (55.0–69.0) | 60.0 (44.0–65.0) | 0.354 |
| AV mean gradient, mm Hg | 40.0 (26.0–49.5) | 40.0 (24.0–62.0) | 40.0 (26.2–47.8) | 0.939 |
| AV peak gradient, mm Hg | 64.0 (45.2–84.8) | 63.0 (46.0–105) | 66.0 (45.0–84.0) | 0.938 |
| AR > mild | 0.797 | |||
| No | 57 (58.2) | 15 (62.5) | 42 (56.8) | |
| Yes | 41 (41.8) | 9 (37.5) | 32 (43.2) | |
| MR > mild | 0.354 | |||
| No | 61 (62.2) | 18 (72.0) | 43 (58.9) | |
| Yes | 37 (37.8) | 7 (28.0) | 30 (41.1) | |
| Index AVR <19.0 mm true ID | 0.005 | |||
| No | 82 (82.8) | 25 (100) | 57 (77.0) | |
| Yes | 17 (17.2) | 0 (0.00) | 17 (23.0) |
Values are shown as median (interquartile range) for continuous variables and number (percentage) for categorical variables. Group differences are presented as overall P value. aFib indicates atrial fibrillation; AR, aortic regurgitation; AV, aortic valve; AVR, AV replacement; CCS, Canadian Cardiovascular Society; ID, internal diameter; MR, mitral regurgitation; NYHA, New York Heart Association; PCI, percutaneous coronary intervention; STS, Society of Thoracic Surgeons; TIA, transient ischemic attack; ViSAVR, valve in surgical AVR; and ViTAVR, valve in transcatheter AVR.